Form D · Biotechnology
NewcelX Ltd.
Kloten, V8 · CIK 0001783036
Offering snapshot reported Aug 24, 2026 · SEC filing
- Reported sold
- $2.94M Offering amount: $2.94M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 3, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 24, 2026 | Initial | $2,940,234 | No comparison | 5 | SEC filing |
| May 13, 2026 | Initial | $3,428,989 | No comparison | 4 | SEC filing |
| Jul 10, 2025 | Initial | $1,000,000 | No comparison | 3 | SEC filing |
| Apr 14, 2025 | Initial | $2,000,000 | No comparison | 3 | SEC filing |
| Jan 22, 2025 | Initial | $499,999 | No comparison | 1 | SEC filing |
| Oct 21, 2024 | Initial | $7,200,000 | No comparison | 6 | SEC filing |
| Jul 15, 2024 | Initial | $786,660 | No comparison | 2 | SEC filing |
| Apr 3, 2024 | Initial | $1,750,000 | No comparison | 2 | SEC filing |
| Dec 21, 2022 | Initial | $10,000,000 | No comparison | 4 | SEC filing |
| Oct 14, 2022 | Initial | $4,000,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-595172
Including the exercise price of common shares underlying such warrants at an exercise price of $4.437.
Common shares and warrants to purchase common shares
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| None | None |
Source: Form D, filed Aug 24, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Florence Allouche Aknin | Director |
| Florence Allouche Aknin | Director |
| George Apostol | Executive |
| Claudio L.A. Basseti | Director |
| Claudio L. A. Bassetti | Director |
| Nicole Fernandez Mc Govern | Executive |
| Tamar Galili | Director |
| Audrey Greenberg | Director |
| Ronald Hafner | Director |
| Omri Hagai | Executive |
| Chad Hellmann | Executive |
| Eran Iohan | Director |
| Eric Konofal | Executive |
| Myoung Ok Kwon | Director |
| Kfir Molakandov | Executive |
| Liora Oren | Director |
| Stig Lokke Pedersen | Director |
| Michel Revel | Director, Executive |
| Gian Marco Rinaldi | Director |
| Gian Marco Rinaldi De La Cruz | Director |
| Olivier Samuel | Director |
| Elena Thyen Pighin | Executive |
| Ronen Twito | Director, Executive |
| Anthony Walsh | Director |
| Alexander C. Zwyer | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Hohstrasse 1
Kloten, V8, 8302
Phone: 41 44 512 21 50
Kloten, V8, 8302
Phone: 41 44 512 21 50